2803 related articles for article (PubMed ID: 7546824)
1. Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-alpha combination therapy.
Fosså SD; Aamdal S; Naume B; Gallati H
Acta Oncol; 1995; 34(5):599-603. PubMed ID: 7546824
[TBL] [Abstract][Full Text] [Related]
2. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.
Grimm EA; Smid CM; Lee JJ; Tseng CH; Eton O; Buzaid AC
Clin Cancer Res; 2000 Oct; 6(10):3895-903. PubMed ID: 11051235
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
4. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
6. Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy.
Nukui A; Masuda A; Abe H; Arai K; Yoshida KI; Kamai T
BMC Cancer; 2017 May; 17(1):372. PubMed ID: 28545581
[TBL] [Abstract][Full Text] [Related]
7. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants.
McIntyre CA; Chapman K; Reeder S; Dorreen MS; Bruce L; Rodgers S; Hayat K; Schreenivasan T; Sheridan E; Hancock BW
Eur J Cancer; 1992; 28(1):58-63. PubMed ID: 1567693
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
10. Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.
Landmann R; Keilholz U; Scheibenbogen C; Brockhaus M; Gallati H; Denz H; Bargetzi M; Ludwig C
Cancer Immunol Immunother; 1994 Feb; 38(2):113-8. PubMed ID: 8306366
[TBL] [Abstract][Full Text] [Related]
11. Rapid cytokine release in cancer patients treated with interleukin-2.
Weidmann E; Bergmann L; Stock J; Kirsten R; Mitrou PS
J Immunother (1991); 1992 Aug; 12(2):123-31. PubMed ID: 1504053
[TBL] [Abstract][Full Text] [Related]
12. Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies.
Raziuddin S; Sheikha A; Abu-Eshy S; al-Janadi M
Cancer; 1994 May; 73(9):2426-31. PubMed ID: 8168046
[TBL] [Abstract][Full Text] [Related]
13. Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy.
Soubrane C; Mouawad R; Ichen M; Suissa J; Borel C; Vuillemin E; Benhammouda A; Bizzari JP; Weil M; Khayat D
Clin Exp Immunol; 1994 Feb; 95(2):232-6. PubMed ID: 8306497
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
15. Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapy.
Belldegrun A; Pierce W; Sayah D; deKernion J; Wallach D; Aderka D; Figlin RA
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):175-80. PubMed ID: 8385988
[TBL] [Abstract][Full Text] [Related]
16. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.
Lauerova L; Dusek L; Simickova M; Kocák I; Vagundová M; Zaloudík J; Kovarík J
Neoplasma; 2002; 49(3):159-66. PubMed ID: 12098001
[TBL] [Abstract][Full Text] [Related]
17. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
18. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
19. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients.
Bernengo MG; Quaglino P; Cappello N; Lisa F; Osella-Abate S; Fierro MT
Melanoma Res; 2000 Feb; 10(1):55-65. PubMed ID: 10711641
[TBL] [Abstract][Full Text] [Related]
20. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes.
Mangge H; Kenzian H; Gallistl S; Neuwirth G; Liebmann P; Kaulfersch W; Beaufort F; Muntean W; Schauenstein K
Arthritis Rheum; 1995 Feb; 38(2):211-20. PubMed ID: 7848311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]